Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Substrate reduction therapy in...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
Bibliographic Details
Main Authors:
Lachmann, R
,
Wright, N
,
Parker, A
,
Ramaswarm, U
,
Coleman, M
,
Roos, J
,
Burnstein, R
,
Gillard, J
,
Harding, S
,
Platt, F
,
Wraith, J
,
Cox, T
Format:
Journal article
Published:
2006
Holdings
Description
Similar Items
Staff View
Similar Items
Miglustat - A viewpoint
by: Platt, F, et al.
Published: (2003)
Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005)
Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C.
by: Lachmann, R, et al.
Published: (2004)
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
by: Elstein, D, et al.
Published: (2004)
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
by: Andersson, U, et al.
Published: (2004)